Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
Learn more
This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.


The first choice of RSV prevention is Nirsevimab; alternatively, palivizumab is to be considered in case of unavailability of Nirsevimab.